ArticleVox sanguinis2026
The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Up to 19-year cryopreservation does not impair hematopoietic progenitor function in cord blood: a 1129-unit analysis from the largest Korean public cord blood bank.Stem cells translational medicine · 2026Article
- The impact of the cryopreservation period on the CD34+ cell viability of cryopreserved cord blood units.Vox sanguinis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesCord blood (CB) is an important source for haematopoietic stem cell transplantation because of its long-term cryopreservation. However, concerns remain regarding the potential decline in CB quality with prolonged cryopreservation. This study aimed to evaluate the post-thaw viability of CD45+ and CD34+ cells in CB units and to investigate how their viabilities change over prolonged cryopreservation. MATERIALS AND
methodsWe enrolled 726 CB units that underwent pre-transplantation examination from May 2006 through June 2023. Post-thaw viabilities of CD45+ and CD34+ cells were analysed in relation to cryopreservation period and across 4-year cryopreservation groups.
resultsThe mean post-thaw viabilities were 60.5% for CD45+ cells and 91.2% for CD34+ cells. CD45+ cell viability showed a positive correlation with the cryopreservation period (r = 0.304, p < 0.001); however, no consistent trend was observed among the cryopreservation period groups. In contrast, CD34+ cell viability showed a significant negative correlation with the cryopreservation period (r = - 0.306, p <0.001) and decreased, with units cryopreserved for 1-4 years and 5-8 years having significantly higher viabilities than those cryopreserved for 9-12 years and 13-16 years.
conclusionOur findings demonstrate that the post-thaw viabilities of CD45+ and CD34+ cells in cryopreserved CB units exceed internationally accepted standards, with CD34+ cell viability showing a tendency to decline with prolonged cryopreservation. These results underscore the importance of securing an adequate CD34+ cell dose at the time of cryopreservation to maintain the long-term quality and clinical utility of CB units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.